AIM - AIM ImmunoTech Inc.
About AIM ImmunoTech Inc. (https://aimimmuno.com)
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Thomas K. Equels | Executive Vice Chairman, Chief Executive Officer & President | 1953 | $681,316 USD |
| Peter W. Rodino | Chief Operating Officer, Executive Director of Governmental Relations, General Counsel & Secretary | 1951 | $386,181 USD |
| Robert Dickey | Chief Financial Officer | 1956 | $108,420 USD |
| Ann Marie E. Coverly | Director of Administration & Human Resources and Deputy Investor Relations Coordinator | – | – |
| Christopher Nicodemus FACP | Member of Scientific Advisory Board & Consulting Science Officer | – | – |